BERKELEY, CA--(Marketwired - Sep 3, 2015) - Dynavax Technologies Corporation (
The live or replayed versions of the webcast of the Newsmakers presentation will be available by visiting the "Investors" section of the Dynavax website or may be reached directly at:
Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information visit www.dynavax.com.
Chief Financial Officer